



SOMERLEY CAPITAL LIMITED

20/F., China Building, 29 Queen's Road Central, Hong Kong

Telephone: 2869 9090 Fax: 2526 2032 E-Mail: somerley@somerley.com.hk

The Board of Directors
Lepu Biopharma Co., Ltd.
Room C280, Building 1
No. 1628, Su Zhao Road
Minhang District, Shanghai
The PRC

January 16, 2024

Dear Sirs,

CONTINUING CONNECTED TRANSACTION

We refer to the circular issued by Lepu Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on the even date in relation to, among others, the captioned matters (the “**Circular**”). Capitalised terms used in this letter shall have the same meanings as those defined in the Circular, unless the context requires otherwise.

We hereby confirm that as of the Latest Practicable Date,

- (i) we have no shareholding, direct or indirect, in any member of the Group or any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group;
- (ii) we have no interest, direct or indirect, in any assets which have been since December 31, 2022, the date up to which the latest published audited financial statements of the Group were made up, acquired or disposed of by or leased to any member of the Group, or are proposed to be acquired or disposed of by or leased to any member of the Group; and
- (iii) we have given and have not withdrawn our written consent to the issue of the Circular with the inclusion of our letter of advice and references to our names in the form and context in which they appear.

We further consent to our letter of advice and this letter to be made available for public inspection as described in the paragraph headed “8. DOCUMENTS ON DISPLAY” in the Appendix I to the Circular.

Yours faithfully,
for and on behalf of
SOMERLEY CAPITAL LIMITED

Calvin Leung
Director